IMCR250117C40000
- 0.30
- 0.000.00%
Immunocore Newsroom
Immunocore Advances Half-Life Extended Cancer Treatment With First Patient Dosed
Express News | Immunocore Announces First Patient Dosed in the Phase 1 Trial of Imc-P115C, a Half-Life Extended (Hle) Immtac Candidate in Patients With Tumors That Express Prame
Jefferies Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $45
Express News | Immunocore Begins Phase 1/2 Trial of IMC-R117C, The First Immunotherapy Targeting PIWIL1 In Advanced Gastrointestinal Cancers
Immunocore Holdings (NASDAQ:IMCR) Has Debt But No Earnings; Should You Worry?
Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley Downgrades Immunocore Holdings to Equalweight From Overweight, Cuts Price Target to $35 From $74
Morgan Stanley Downgrades Immunocore(IMCR.US) to Hold Rating, Cuts Target Price to $35
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Immunocore Enrolls First Patient in Phase 3 Uveal Melanoma Trial
Express News | Eortc and Immunocore Announce Enrolment of First Patient Onto the Only Active Phase 3 Adjuvant Trial in Uveal Melanoma
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
Immunocore Secures Reimbursement Agreement In England For KIMMTRAK To Treat HLA-A*02:01-Positive Adults With Unresectable Or Metastatic Uveal Melanoma
Express News | Immunocore Announces Reimbursement Agreement in England for Kimmtrak▼ for the Treatment of Hla-a*02:01-Positive Adults With Unresectable or Metastatic Uveal Melanoma
Corcept Shares Rise More Than 60% in Three Months: Here's Why
Goldman Sachs Maintains Immunocore(IMCR.US) With Buy Rating, Announces Target Price $74